Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations

Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations

Public reimbursement systems face the challenge of balancing provision of needed treatments and the reality of limited resources. Canada has a complex system for drug approval and public reimbursement, with jurisdiction divided between the federal government and the provinces/territories. A pivotal...

Full description

Bibliographic Details
Main Authors:	Louise Binder, Majd Ghadban, Christina Sit, Kathleen Barnard
Format:	Article
Language:	English
Published:	MDPI AG 2022-03-01
Series:	Current Oncology
Subjects:	health technology assessment HTA oncology treatment access quality adjusted life years treatment access drug access drug reimbursement
Online Access:	https://www.mdpi.com/1718-7729/29/3/127

Similar Items

Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs
by: Oriol Solà-Morales, et al.
Published: (2019-01-01)

Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action
by: Sandeep Sehdev, et al.
Published: (2024-03-01)

The reimbursement decision speed for oncology new drugs in China and its determinant factors
by: Xingyue Zhu, et al.
Published: (2023-10-01)

The timelines for the price and reimbursement authorization in Italy 2018–2020
by: Valentina Gallo, et al.
Published: (2022-12-01)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
by: Bérengère Macabeo, et al.
Published: (2023-12-01)

Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
by: Virginia Ronco, et al.
Published: (2021-12-01)

Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries
by: Szczepan Jakubowski, et al.
Published: (2024-03-01)

Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries
by: Jesper Jørgensen, et al.
Published: (2020-01-01)

Is It Time to Commit to a Process to Re-Evaluate Oncology Drugs? A Descriptive Analysis of Systemic Therapies for Solid Tumour Indications Reviewed in Canada from 2017 to 2021
by: Sandeep Sehdev, et al.
Published: (2022-03-01)

Value Insider Season 1 Episode 1: The Importance of Payers and HTA: How Did We End Up Here? (Introduction to Value) [Podcast]
by: Drummond MF, et al.
Published: (2022-09-01)

HTA regulation: how is Italy moving?
by: Francesca Patarnello
Published: (2024-03-01)

Accelerating patient access to oncology medicines with multiple indications in Europe
by: R. Lawlor, et al.
Published: (2021-01-01)

Affordability of oncology drugs: accuracy of budget impact estimations
by: Joost W. Geenen, et al.
Published: (2020-01-01)

Are payers treating orphan drugs differently?
by: Joshua P. Cohen, et al.
Published: (2014-01-01)

Access and reimbursement pathways for digital health solutions and in vitro diagnostic devices: Current scenario and challenges
by: Andrea Mantovani, et al.
Published: (2023-02-01)

Decision-making on listing new medicines for public funding in New Zealand: the case of 'new' type 2 diabetes medications
by: Caroline Stretton, et al.
Published: (2022-01-01)

Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price? A study of reimbursement reports
by: Joost J. Enzing, et al.
Published: (2022-08-01)

Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021
by: Catherine Lau, et al.
Published: (2022-10-01)

Strategic discussion on funding and access to therapies targeting rare diseases in Spain: an expert consensus paper
by: N. Zozaya, et al.
Published: (2023-02-01)

Tunneled vascular access surgery in pediatric oncology; Experience from a national pediatric oncology center
by: Ceder H. van den Bosch, et al.
Published: (2023-12-01)

Evaluation of alignment of the reimbursement medicines list for children in Albania with the WHO essential medicines list for children
by: E. Petro, et al.
Published: (2024-12-01)

What is the role of antineoplastic drug safety in reimbursement decision making?
by: A. S. Kolbin, et al.
Published: (2018-11-01)

Reimbursement decision-making system in Poland systematically compared to other countries
by: Aneta Mela, et al.
Published: (2023-10-01)

The influence of accessibility of anticancer drug therapy on the target indicators of the oncological service
by: V. V. Petkau, et al.
Published: (2021-06-01)

Value Insider Season 1 Episode 5: What Other Aspects of Value May Be Relevant? (Societal Impact) [Podcast]
by: Garrison LP, et al.
Published: (2022-11-01)

Value Insider Season 1 Episode 6: How Will Market Access and Value Demonstration Evolve? (Future Outlook) [Podcast]
by: Kanavos PG, et al.
Published: (2022-12-01)

Value Insider Season 1 Episode 3: How Does Budget Impact and Affordability in Healthcare Work? (BI and Affordability) [Podcast]
by: Sullivan SD, et al.
Published: (2022-10-01)

Value Insider Season 1 Episode 4: How are Costs Measured, and How are CEAs Constructed and Used? (CEA) [Podcast]
by: Rutten-van Mölken MPMH, et al.
Published: (2022-11-01)

Value Insider Season 1 Episode 2: How to Measure Quality of Life and Utility? (QoL) [Podcast]
by: Devlin NJ, et al.
Published: (2022-10-01)

THEORETICAL AND PRACTICAL ASPECTS REGARDING THE ADJUSTMENT AND REIMBURSEMENT OF VALUE ADDED TAX
by: CIUMAG MARIN, et al.
Published: (2021-10-01)

Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe
by: Carin A. Uyl-de Groot, et al.
Published: (2020-08-01)

Navigating Gene Therapy Access: The Case of Bulgaria in the Context of the EU Regulatory Landscape
by: Kostadin Kostadinov, et al.
Published: (2024-02-01)

Balancing medical innovation and affordability in the new healthcare ecosystem in China: Review of pharmaceutical pricing and reimbursement policies
by: Vivian Chen, et al.
Published: (2023-12-01)

Impact of Drug Pressure versus Limited Access to Drug in Malaria Control: The Dilemma
by: Chinedu Ogbonnia Egwu, et al.
Published: (2022-01-01)

An integrated valuation model for payer and investor
by: Mark Nuijten, et al.
Published: (2022-12-01)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
by: Karolina Badora, et al.
Published: (2017-01-01)

Access to precision medicine in Thailand: a comparative study
by: Nisita Jirawutkornkul, et al.
Published: (2022-02-01)

Drug pricing and reimbursement decision making systems in Mongolia
by: Gereltuya Dorj, et al.
Published: (2017-12-01)

MATHEMATICAL MODEL OF REIMBURSEMENT DECISION MAKING IN RUSSIA. RESULTS OF VIM LIST FOR 2016
by: A. S. Kolbin, et al.
Published: (2016-04-01)

Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption
by: John Hair, et al.
Published: (2022-10-01)